Pharmacol 240, 319-323, (1993). Bergeron, R., Debonnel, G., & De Montigny, C. View abstract in PubMed Post navigationPreviousPrevious post:Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex.NextNext post:Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer’s disease correlates with CA1 pyramidal cell loss.Related PostsAnavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)August 26, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021Anavex Life Sciences Announces Closing of $50 Million Registered Direct OfferingJune 24, 2021
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)August 26, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021
